Latest article
Fierce Pharma Asia—AstraZeneca-Junshi PD-1 deal; Takeda’s $1.2B diabetes selloff, Ovid epilepsy collab pullout
In a strangely structured deal, AstraZeneca has nationwide licensed Junshi Biosciences' PD-1 inhibitor for only one indication in China. Takeda continued to sell...
International Clary Sage Important Oil Market by COVID-19 Impression Evaluation by Market Analysis Retailer...
Global Muscatel Essential Oil Market Players, Business Approaches, and Geographical Analysis in the COVID-19 Pandemic Pan
Report on "Clary Sage Essential Oil Market Published...
New diabetes medication efficient strategy to deal with kidney illness
New diabetes drugs to effectively fight kidney diseaseNearly 7,000 Australians could be saved from end-stage kidney disease in the next 20 years if we...